- Big Health Care Disparities Persist Across the U.S., New Report Finds
- Teens Often Bullied Online About Their Weight: Study
- Work That Challenges Your Brain Helps You Stay Sharp With Age
- Urine Test Might Spot Head-and-Neck Cancers Early
- Many Seniors Are Overmedicated, But ChatGPT Might Prevent That
- Antipsychotics May Do Great Harm to People With Dementia: Report
- Two-Drug Combo Curbs Drinking for People Battling Severe Alcoholism
- Most Homeless Americans Are Battling Mental Illness
- FDA Recalls Heart Failure Devices Linked to Injuries and Deaths
- COVID Does Not Spur Asthma in Kids, Study Finds
Vonvendi Approved to Control Bleeding Disorder
Vonvendi has been approved to treat adults with von Willebrand disease (VWD), the most common inherited bleeding disorder.
VWD, affecting about 1 percent of the U.S. population, is caused by lack of a protein that’s essential for blood clotting. People with the disorder can develop severe bleeding from the nose, gums, intestines, muscles and joints. Women with VWD also can bleed excessively after a menstrual period or after giving birth.
Vonvendi, a genetically engineered (recombinant) form of the missing protein, was evaluated in clinical studies of 69 adults with VWD. Itching was the most common side effect, the FDA said Tuesday in a news release.
Vonvendi is produced by Baxalta, based in Westlake Village, Calif.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.